Does Your Insurance Cover Wegovy?
HOW TO FIND OUT
Does Your Insurance Cover Wegovy?
HOW TO FIND OUTCall Your Insurance Provider 📞
Call the number on your insurance card and ask:
- "Is semaglutide (Wegovy) on my plan's formulary?"
- "Do you cover it for weight management, or only for diabetes?"
- "What tier is it on?" (lower tier = lower copay)
- "Is prior authorization required?"
Pro tip: Write down the representative's name and any reference number. Verbal confirmations aren't binding, but documentation helps if there's a dispute later.
What Is a Formulary?
A formulary is your insurance plan's list of approved medications. If Wegovy isn't on your formulary, your plan won't cover it—even with a prescription.
The reality: In KFF’s employer survey, only 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) covered GLP-1 medications like Wegovy when used primarily for weight loss.16 Many plans explicitly exclude weight-loss drugs entirely.
Common requirements: BMI ≥30 or ≥27 + comorbidity, 6-12 months lifestyle modification
⚠️ 2026 Open Enrollment Alert
Some employers and insurers (BCBS Massachusetts, Health New England, Kaiser) are dropping or restricting GLP-1 weight loss coverage for 2026. If you're choosing a plan now, verify Wegovy coverage BEFORE enrolling.
Ask your HR or insurer: "Does this plan cover semaglutide (Wegovy) for weight management in 2026?"
Which Insurers Cover Wegovy?
Coverage varies significantly by insurer and plan type. About 43% of large employer plans cover GLP-1 medications. For a complete breakdown of which insurers cover Wegovy and their requirements, see our insurance directory.
Medicaid Coverage Guide
State-by-State Coverage
Only 13 states (as of January 2026) covered GLP-1s for weight loss through Medicaid,8 and the landscape is shifting—some states are adding coverage while others are cutting it due to costs.9
BALANCE model: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed.12
Medicaid requirements are typically stricter than commercial plans (BMI ≥35-40 vs ≥30), and coverage can change mid-year. Always verify current coverage with your state.
Medicare Coverage Guide
Medicare Coverage Is Changing
Heart health: Wegovy may be covered under Part D to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight, subject to the plan’s formulary, prior authorization and exceptions process (FDA-approved: injection March 8, 2024 (Wegovy injection); tablets December 22, 2025 (Wegovy tablets)). Note: Wegovy has no FDA approval for sleep apnea. Learn more in our Medicare guide →
Medicare and weight-loss GLP-1s: the Medicare GLP-1 Bridge
Through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), a temporary CMS demonstration that runs outside the Part D benefit, people with eligible Part D coverage can get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for $50 a month, if they meet CMS’s eligibility criteria and their prescriber gets prior authorization.
Source: CMS, Medicare GLP-1 Bridge · Facts in this box verified October 5, 2026
Does your employer plan exclude all weight loss meds?
If your employer-sponsored plan excludes all weight loss medications, you can advocate for policy change. Request that your HR department add GLP-1 coverage for the next enrollment period—and encourage coworkers to do the same.
Download HR Request Letter (PDF) →Download Coworker Sample Letter (PDF) →Learn more about fighting weight loss exclusions →
Filing for Prior Authorization
HOW TO GET PREPARED
Filing for Prior Authorization
HOW TO GET PREPAREDWhat Is Prior Authorization?
Prior authorization (PA) is your insurer's way of pre-approving expensive medications before they'll cover them. For Wegovy, this means your doctor submits documentation proving you meet the medical criteria—and the insurer decides whether to pay.
Why it matters: A well-prepared PA submission is the difference between approval and denial. Missing documentation, incorrect codes, or incomplete medical history are the most common reasons Wegovy PAs get rejected. Get the PA checklist →
What Your Doctor Needs
- Current BMI (measured within 30 days)
- Comorbidity diagnoses (hypertension, diabetes, sleep apnea, high cholesterol)
- 3-6 months of lifestyle modification documentation
- Prior weight-loss medications tried (if any)
- Letter of medical necessity
Timeline: Most employer and ACA plans must decide within 15 days (72 hours if urgent). Follow up by day 5.
Once You're Approved
SAVINGS & MAINTENANCE
Once You're Approved
SAVINGS & MAINTENANCEYou're Approved — Now Maximize Your Savings
With the Wegovy savings card, you can pay as low as $25/month for Wegovy. Here's how to activate it and avoid pharmacy surprises.
How to activate your Wegovy savings card
With insurance coverage: As low as $25/month
- Max savings: $100 per 1-month fill
- Annual cap: No annual cap amount is stated in the terms
Eligibility requirements:
- Commercial insurance that covers Wegovy
- NOT Medicare, Medicaid, VA, or TRICARE
- U.S. resident, age 18+
Terms and eligibility change periodically; confirm current details at the link below.
Activate here: novocare.com/wegovy/savings-offer
See complete savings card guide →
Save Your Card Details
After activating, save your BIN, PCN, and Group number (pharmacy processing codes). You'll need these at the pharmacy.
What to say at the pharmacy
When picking up your prescription:
"I have a Wegovy prescription with prior authorization. My PA reference number is [NUMBER]. I also have a Wegovy savings card—here's the BIN and PCN. Can you confirm my copay before filling?"
Common pharmacy issues and fixes:
"PA not on file"
Ask them to call insurance or your doctor to verify. Say: "The PA was approved on [DATE]. Can you call the insurance PA department to verify the authorization?"
"Savings card not working"
Confirm the BIN and PCN are entered correctly. If still not working, call the Wegovy Savings Offer line at 1-888-793-1218.
"Not in stock"
Ask when it will be available or try another pharmacy. Some patients have better luck with specialty pharmacies.
How to prepare for Wegovy renewal
Monthly tracking (for your records and renewal):
- Weight (same scale, same conditions)
- Blood pressure
- A1C (quarterly)
- Side effects or issues
- Lifestyle activities (exercise, diet tracking)
60 days before expiration:
- Contact your doctor's office to initiate renewal
- Confirm you've met your plan's weight loss threshold (typically 5%)
- Gather documentation showing your progress
Don't Wait Until the Last Minute
A reauthorization is a new review, so allow time (most employer and ACA plans can take up to 15 days). Starting early prevents gaps in your medication supply.
Strategies for Restrictive Coverage
FORMULARY & TIER EXCEPTIONS
Strategies for Restrictive Coverage
FORMULARY & TIER EXCEPTIONSIf Wegovy is Not on Formulary → Formulary Exception
Your goal: Add Wegovy to your plan's covered drug list. What to do if Wegovy is not covered by insurance →
- Your prescriber must initiate the formulary exception
- Submit medical necessity documentation
- Include your obesity-related complications and clinical evidence
Timeline: Individual and small-group ACA plans must decide within 72 hours (24 hours if urgent); employer plans follow their own exception process, usually within 15 days
If Wegovy is High-Tier → Request a Tier Exception
Your goal: Move Wegovy from Tier 3-4 to Tier 1-2 for lower costs.
- Contact your insurance's formulary exception department
- Have your doctor submit a tier exception request
- Include documentation of failed trials with preferred medications
Timeline: Depends on your plan; ask when you file
Appeals & Reauthorization
IF DENIED OR RENEWING
Appeals & Reauthorization
IF DENIED OR RENEWINGWhy Appeals Matter
Initial denials are a filter, not a final answer. Over 65% of prior authorization appeals succeed1—yet fewer than 1% of denied claims are ever appealed.2 Insurers rely on patient inaction. See appeal success rate data →
Just got your denial letter? Start with our Wegovy Denied crisis guide for what to do right now.
Common denial reasons include "not medically necessary," step therapy requirements, and Wegovy not covered by insurance. Each has specific appeal strategies that work.
Common Denials → Your Move
Timeline: Internal appeal 30 days → External review 45 days
Your GLP-1 coverage,
denied approved
65%+ of appeals succeed — but only if you file one. Honest Care writes personalized, evidence-backed appeal letters to help you fight back.
Ready to appeal?
Get Your Free LetterNo Insurance Guide
SELF-PAY OPTIONS
No Insurance Guide
SELF-PAY OPTIONSNeed the Lowest Price Now?
If you're paying out of pocket: Oral Wegovy starts at $149/month, or injectable at $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026.
NEW: Oral Wegovy (pill form)
FDA approved December 22, 2025. Available doses and pricing:
- 1.5 mg (starter): $149/month
- 4 mg: $199/month
- 9 mg: $299/month
- 25 mg (maintenance): $299/month
Cheapest Self-Pay Option
Oral Wegovy at $149–$299/month is the most affordable way to start without insurance. Same active ingredient (semaglutide) as injectable Wegovy.
Injectable Wegovy self-pay through NovoCare
NovoCare self-pay pricing (as of Jan 2026):
- Intro offer (new patients): $199/month for the first two fills (0.25 mg and 0.5 mg), through December 31, 2026
- Regular self-pay: $349/month ($399 for Wegovy HD 7.2 mg)
Where to get it: NovoCare.com, 70,000+ pharmacies, or home delivery
How to use the Wegovy savings card without insurance
With commercial insurance that doesn't cover Wegovy: No current Wegovy card price for plans that don’t cover it; self-pay pricing applies ($349/month ($399 for Wegovy HD 7.2 mg)).
Savings card eligibility:
- Must have commercial insurance that covers Wegovy
- NOT for Medicare, Medicaid, VA, or TRICARE
- Max savings: $100 per 1-month fill (as of January 2, 2026)
Important
The savings card only lowers a copay your plan already covers. If your plan doesn't cover Wegovy or you're uninsured, use NovoCare self-pay or oral Wegovy instead.
How to apply for Wegovy patient assistance
Novo Nordisk PAP Patient Assistance Program:
- Wegovy is not on Novo Nordisk’s Patient Assistance Program list
- The PAP covers insulins, Ozempic and other listed products, not Wegovy
- Program details: novocare.com/diabetes/help-with-costs/pap.html
See complete patient assistance guide →
Worth Checking
Call NovoCare at 1-888-809-3942 to ask about current Wegovy savings and self-pay options.
TrumpRx direct-purchase option (Live since February 2026)
TrumpRx.gov launched on February 5, 2026. TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price):
- Price: NovoCare self-pay pricing ($349/month ($399 for Wegovy HD 7.2 mg); list price $1,349/month)
- Who can use it: If you have government insurance, ask NovoCare whether you can use self-pay pricing
- Medicare patients: The Medicare GLP-1 Bridge costs $50 per monthly fill if you qualify
For Medicare Patients
If you have Medicare Part D, check the Medicare GLP-1 Bridge first: Wegovy costs $50 per monthly fill (July 1, 2026 – December 31, 2027) if you meet CMS’s criteria and your prescriber gets prior authorization.
Alternatives
OTHER GLP-1 OPTIONS
Alternatives
OTHER GLP-1 OPTIONSIf Wegovy remains inaccessible, several FDA-approved alternatives like Wegovy and Saxenda, plus off-label options, may provide similar benefits depending on your insurance coverage.
Wegovy vs Zepbound and Saxenda
If Wegovy isn't accessible or affordable, consider alternatives. Zepbound (tirzepatide) is the most effective GLP-1 in trials; coverage for either drug depends on your plan’s formulary. Saxenda (liraglutide) is older but sometimes preferred by insurers.
When deciding which GLP-1 is right for you, consider your weight loss goals, insurance coverage, side effects and budget.
Wegovy vs Mounjaro and Ozempic
While Mounjaro and Ozempic are currently only approved by the FDA for treatment of Type 2 diabetes, it doesn't necessarily mean you won't be able to access these medications.
Off-label prescription of these medications for reducing the risks of developing type 2 diabetes or for treatment of metabolic syndrome have been successful for some—but this depends highly on your insurance plan and clinical profile.
All Coverage Options at a Glance
DECISION MATRIX
All Coverage Options at a Glance
DECISION MATRIX| Insurance Type | Best First Step | Timeline | Monthly Cost | What's Changing |
|---|---|---|---|---|
| Employer/ACA (Good odds) | Check benefits → Submit PA | Up to 15 days (federal limit); often sooner | $25 (with card)5 | — |
| Medicare (CV) (Good odds) | CV risk evaluation | Varies (CV evaluation, then Part D plan PA) | Varies by plan | Bridge (live): $50 per monthly fill for weight loss, if eligible |
| Medicaid (Case-by-case) | Check state coverage | Varies by state | $0 | BALANCE Medicaid track: no state confirmed yet |
| No Insurance (Self-pay only) | Oral Wegovy or NovoCare | Same day | $149–$349 | — |
Color key: Good odds | Case-by-case | Self-pay only
Quick Path Summary
- Employer/ACA: Coverage for weight loss depends on whether your plan includes it. Check benefits, submit PA, appeal if denied.
- Medicare: CV pathway: Wegovy may be covered under Part D for adults with established cardiovascular disease and either obesity or overweight (formulary, prior authorization and exceptions rules apply). For weight loss, the Medicare GLP-1 Bridge is live ($50 per monthly fill, if eligible).
- Medicaid: State-dependent; 13 states (as of January 2026) covered GLP-1s for obesity.
- No Insurance: Oral Wegovy starts at $149/month, injectable at $199/month intro.
COMMON COVERAGE QUESTIONS
Frequently Asked Questions
Start by calling your insurer to check if Wegovy is on your formulary. If covered, your doctor submits a prior authorization (PA) with your BMI, comorbidities, and documentation of lifestyle changes. Follow up within 3-5 days. See our prior authorization guide for detailed requirements by insurer.
Gather before your appointment: current weight/height (for BMI calculation), list of comorbidities with diagnosis dates, documentation of lifestyle changes (diet logs, gym records), and history of prior weight-loss medications tried. See our PA checklist for a complete list.
Most employer and ACA plans must decide within 15 days (one 15-day extension allowed; 72 hours if urgent), and many decide sooner. Call to check status by day 5—don't wait for a letter. If no decision after 7 days, request escalation. See our PA guide for timelines by insurer.
You have the right to appeal. Get your denial letter, note the exact reason, and see our appeals guide for step-by-step instructions.
Now. The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers Wegovy for weight loss for Medicare Part D enrollees who meet CMS’s criteria (Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD) and get prior authorization, at $50 per monthly fill. Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026. See our Medicare guide for eligibility details →
Yes. Many patients use NovoCare ($199/mo intro, $349/mo regular) to start treatment while their PA or appeal processes. If insurance approves later, you can switch to using your coverage. See our cost guide for all payment options.
Start the renewal process 60 days before your authorization expires. Most insurers require proof of 5% baseline weight loss to continue coverage. Track your weight monthly. Your doctor will submit updated documentation showing your progress and continued medical necessity.
Amazing, prompt service
I cannot say enough about this invaluable service they provide! I just know that without them, my appeal would not have been approved so quickly or possibly not at all. When I received my approval, I...
Very happy with Honest Care
Very happy with Honest Care. They delivered my letter in timely manner and had phone call very next day with them to finish and update letter with additional information. Sent to Insurance with record...
Best decision I have ever made!
I just got approved for a whole year with the help of Honest Care! There is no way I could have done it without them. The non-judgement, and caring treatment I received made the whole process move so...
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedReferences
- American Medical Association. (2023). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- Kaiser Family Foundation. (2023). "Claims Denials and Appeals in ACA Marketplace Plans." Analysis of CMS data showing fewer than 1% of denied claims are appealed. kff.org
- Wilding JPH, et al. (2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes Obes Metab. Note: This study is for semaglutide (Wegovy), but similar patterns are expected for GLP-1 class medications including semaglutide (Wegovy). PubMed
- Harvard Health Publishing. (2024). "Prior Authorization: What Is It, When Might You Need It, and How Do You Get It?" health.harvard.edu
- Novo Nordisk. (2025). "Wegovy Savings Card Program." novocare.com
- 42 U.S.C. § 1395w-102. Medicare Part D Prescription Drug Benefits. law.cornell.edu
- U.S. Food and Drug Administration. (2024). "Wegovy Prescribing Information." fda.gov
- Kaiser Family Foundation. (2024). "Medicaid Coverage of and Spending on GLP-1s." kff.org
- State Medicaid policy documents: NC Medicaid, CA DHCS, NH Medicaid, MI Public Radio
- NovoCare. (2025). "Wegovy Vial Pricing." novocare.com
- GoodRx. (2025). "Wegovy Prices, Coupons & Savings Tips." goodrx.com
- Axios. (2025). "Trump announces Medicare coverage of weight-loss drugs." axios.com
Guide Introduction Statistics
- Washington State Office of the Insurance Commissioner. (2025). "Health Plan Prior Authorization Data 2024 Annual Report." Tirzepatide had a 31.2% approval rate across all carriers, implying ~69% denial rate. insurance.wa.gov (PDF)
- Kaiser Family Foundation. (2023). "Claims Denials and Appeals in ACA Marketplace Plans." Analysis of CMS data showing fewer than 1% of denied claims are appealed. kff.org
- American Medical Association. (2024). "Over 80% of prior auth appeals succeed. Why aren't there more?" 83.2% of prior authorization appeals were either partially or fully overturned in 2022. ama-assn.org
- Kaiser Family Foundation. (2025). "2025 Employer Health Benefits Survey." 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025) covered GLP-1 drugs primarily for weight loss. kff.org
- Axios. (November 6, 2025). "Trump announces Medicare coverage of weight-loss drugs." Announcement of the November 2025 Medicare agreement (now the Medicare GLP-1 Bridge). axios.com
- Novo Nordisk. (2025). "NovoCare: Wegovy Pricing." Self-pay, oral Wegovy and Savings Card pricing. novocare.com
Last updated October 6, 2026 · Key facts verified October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.